Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Piroxicam · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | EXPERIMENTAL | - |
| Arm 3 | PLACEBO_COMPARATOR | - |
| Arm 4 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Piroxicam ( BAYl1902) | DRUG | Single dose of 20 mg piroxicam (i.e., 1 piroxicam capsule + 3 placebo capsule) |
| Placebo | DRUG | Single dose of placebo (i.e., 4 placebo capsules) |
Inclusion Criteria: * Signed informed consent available before any study specific tests or procedures are performed * Healthy female subject * Age: 18 to 35 years (inclusive) at the first screening visit * Body mass index (BMI ): 18-30 kg/m² (inclusive) at the first screening visit * Confirmation o...
Piroxicam is being studied for use in postcoital contraception. It is an investigational small molecule in Phase 2 clinical development, evaluated in a completed trial of 72 healthy female participants in Germany. The drug is not approved for this use and remains under clinical investigation.
Piroxicam is being developed by Bayer AG, a company traded under the ticker BAYRY. The drug is currently in Phase 2 clinical development for postcoital contraception, with one completed trial involving 72 participants.
Piroxicam is in Phase 2 clinical development. It is an investigational small molecule being studied for postcoital contraception. The drug has completed one Phase 2 trial, and it is not yet approved for any use.
Piroxicam has one completed clinical trial, NCT01320709, titled "Effect of Piroxicam on Ovulation." This Phase 2, randomized, double-blind, placebo-controlled study enrolled 72 healthy female participants aged 18 years and older in Germany. The trial evaluated the drug for postcoital contraception.
Piroxicam is not FDA approved for postcoital contraception. It is an investigational drug in Phase 2 clinical development, with one completed trial. The drug has not been approved for any indication, and its safety and efficacy for this use are still being studied.